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Abstract
Background—Hispanic females have the highest cervical cancer incidence rate of any racial or
ethnic group in the US, yet relatively little research has examined HPV vaccination among this
fast-growing population. We examined HPV vaccination among a national sample of Hispanic
adolescent females.
Methods—We analyzed provider-verified vaccination data from the 2010-2011 National
Immunization Survey-Teen for Hispanic females ages 13-17 (n=2,786). We used weighted logistic
regression to identify correlates of HPV vaccine initiation (receipt of one or more doses),
completion (receipt of three doses), and follow-through (receipt of three doses among those who
initiated the series).
Results—HPV vaccine initiation was 60.9%, completion was 36.0%, and follow-through was
59.1%. Initiation and completion were more common among older daughters and those whose
parents had received a provider recommendation to vaccinate (all p<0.05). Completion was less
common among daughters who had moved from their birth state (p<0.05). All vaccination
outcomes were less common among daughters without health insurance (all p<0.05). Vaccination
did not differ by parents’ preferred language (all p>0.05), although intent to vaccinate was higher
among Spanish-speaking parents (p<0.01). Spanish-speaking parents were more likely to indicate
lack of provider recommendation (20.2% vs. 5.3%) and cost (10.9% vs. 1.8%) as main reasons for
not intending to vaccinate (both p<0.05).
Conclusions—Many Hispanic females have not received HPV vaccine. Several factors,
including provider recommendation and health insurance, are key correlates of vaccination.
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Impact—HPV vaccination programs targeting Hispanics are needed and should consider how
potential barriers to vaccination may differ by preferred language.
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Introduction
Oncogenic human papillomavirus (HPV) types cause virtually all cases of cervical cancer
(1, 2). National data indicate that Hispanic females ages 14-59 have the second highest
prevalence of HPV infection of any racial or ethnic group in the United States (US), with
44% infected with at least one type of HPV and 31% infected with an oncogenic HPV type
(3). Hispanic women have the highest cervical cancer incidence rate of any racial or ethnic
group in the US (4). The cervical cancer incidence rate among Hispanic women is 74%
higher than that of non-Hispanic white women, and the cervical cancer mortality rate is 48%
higher among Hispanic women (5).
Given this substantial burden of HPV infection and related disease among Hispanic females,
HPV vaccination may be of particular importance for this population. HPV vaccine has been
available for females in the US since 2006. Both the bivalent and quadrivalent HPV
vaccines offer protection against oncogenic HPV types 16 and 18 (which cause over 70% of
cervical and anal cancers and lower percentages of other cancer types (2)), and the
quadrivalent vaccine offers protection against types 6 and 11 (which cause almost all genital
warts (6)). The Advisory Committee on Immunization Practices (ACIP) currently
recommends that adolescent females ages 11-12 receive three doses of prophylactic HPV
vaccine, with catch-up vaccination through age 26 (7). As of 2012, only 53.8% of adolescent
females in the US had received the first dose of the HPV vaccine and 33.4% had received all
three recommended doses (8). Importantly, annual increases in HPV vaccine coverage
among adolescent females have stalled (9, 10). Even with this moderate HPV vaccine
coverage, the prevalence of HPV types included in the bivalent and quadrivalent HPV
vaccines has already begun to decrease among adolescent females (11).
Little research has examined HPV vaccination among Hispanics compared to research on
other racial and ethnic groups. Knowledge about HPV and HPV vaccine tends to be modest
among Hispanic adults (12-17), though most Hispanic parents are willing to vaccinate their
adolescent daughters (17-21). Recent data suggest that HPV vaccine initiation (receipt of at
least one dose) may be higher among Hispanic adolescent females compared to non-
Hispanic whites (8), though Hispanics may be less likely to complete the three-dose series
after receiving the first dose (8, 22). Among Hispanic females, data suggest HPV vaccine
coverage is lower among those with less US acculturation (23, 24). Acculturation can be
defined as “a process of cultural adaptation that occurs when groups of individuals from
different cultures come into contact, leading to changes in the cultural patterns of either or
both groups”(25). Acculturation is a complex construct that has been measured in several
ways in past research, ranging from proxy measures (e.g., preferred language) to
multidimensional scales (26).
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Many of these past studies examining HPV vaccination among Hispanic females included
participants from a limited geographic area (13-21, 23), which may reduce the
generalizability of results. Further, few of these studies identified correlates of vaccination,
perhaps due to small samples or lack of variation in vaccine uptake among respondents.
Identifying correlates is important for planning future programs to increase HPV vaccination
among Hispanics. We analyzed provider-verified vaccination data from a national sample of
Hispanic adolescent females from the National Immunization Survey-Teen (NIS-Teen) to
provide further information about HPV vaccine coverage among Hispanic females and
identify correlates of vaccination. Given that Hispanics are one of the fastest growing US




We conducted a secondary data analysis of publicly available data from the NIS-Teen (29,
30), which has been described extensively elsewhere (31). Briefly, the Centers for Disease
Control and Prevention (CDC) conducts the NIS-Teen annually to examine vaccination
among adolescents ages 13 to 17 in the US. We examined NIS-Teen data from 2010 and
2011, the two most recent years with available data at the time of analyses.
The NIS-Teen collects data using both a random-digit-dialed (RDD) telephone survey with
parents and a mailed survey of adolescents’ healthcare providers. The RDD sampling frame
for the 2010 NIS-Teen contained landline telephones, and the 2011 NIS-Teen used a dual-
frame sampling approach with independent RDD samples of landline and cellular telephones
(32, 33). A complex stratified sampling strategy ensures that the NIS-Teen obtains a national
probability sample. If a sampled household had multiple adolescents ages 13-17, one child
was randomly selected as the index child for the NIS-Teen. The 2010 NIS-Teen had a
household response rate of 58.0% (34), and the 2011 NIS-Teen had household response
rates of 57.2% for landline households and 22.4% for cellular households (35). For the
current study, we report data on a total of 2,786 Hispanic adolescent females from the 2010
and 2011 NIS-Teen.
Data collection for the NIS-Teen received approval from the National Center for Health
Statistics Research Ethics Review Board; analysis of deidentified NIS-Teen data is exempt
from the federal regulations for the protection of human research participants. The
Institutional Review Board at The Ohio State University deemed this study exempt from
review.
Measures
We examined three HPV vaccination outcomes as our primary outcome variables (34): 1)
initiation: receipt of at least one dose of the three-dose HPV vaccine series; 2) completion:
receipt of all three doses; and 3) follow-through: receipt of all three doses among only those
who initiated the vaccine series (i.e., completion among initiators). The denominators
differed for completion (all Hispanic adolescent females) and follow-through (only those
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Hispanic adolescent females who received the first dose). Vaccination data were based on
provider-verified vaccination records.
Among parents of unvaccinated daughters, we examined intent to get their daughters HPV
vaccine in the next year. The NIS-Teen assessed intent by asking these parents, “How likely
is it that [TEEN] will receive HPV shots in the next 12 months?” Response options included
“not likely at all,” “not too likely,” “not sure/don’t know,” “somewhat likely,” and “very
likely” (coded 1-5). Parents who indicated “not likely at all,” “not too likely,” or “not sure/
don’t know,” were then asked, “What is the main reason [TEEN] will not receive HPV shots
in the next 12 months?” Parents could indicate multiple responses for this open-ended item,
with the CDC coding responses into categories.
The NIS-Teen collects data on several demographic and health-related characteristics (Table
1). If someone other than the mother in a participating household completed the parent
survey, this individual provided information about the mother’s age, education level, and
marital status. We examined daughter’s race (white, black, or other) since the NIS-Teen
assessed race separately from ethnicity. We examined if daughters lived in the state where
they were born at the time of data collection (i.e., geographic mobility) and whether parents
completed the NIS-Teen telephone survey in English or Spanish (i.e., preferred language).
The preferred language variable served as a proxy measure of acculturation for this study.
Language preference is a commonly used proxy for acculturation, and it correlates with
acculturation scales and is a domain within several such scales (26). Parents also indicated
whether they had ever heard of HPV and of HPV vaccine, and if they had ever received a
healthcare provider recommendation to have their daughters receive HPV vaccine.
Data Analysis
We used logistic regression to identify correlates of our three primary HPV vaccination
outcomes (initiation, completion and follow-through). For each outcome separately, we
entered all variables associated with the outcome in bivariate models (p<0.05) into a
multivariate logistic regression model. The multivariate models produced adjusted odds
ratios (ORs) and 95% confidence intervals (CIs). Similar to previous analyses of NIS-Teen
data (36), we did not examine parents’ awareness of HPV and of HPV vaccine as potential
correlates. We excluded these variables as candidates because awareness was likely due to a
healthcare provider’s recommendation or actual vaccination for some parents, while, for
other parents, awareness preceded provider interaction or vaccination.
We believed differences in additional outcomes by acculturation would be important for
guiding future intervention efforts, so we determined if parents’ intent to vaccinate (linear
regression) and reasons for not intending to vaccinate (logistic regression) differed by
parents’ preferred language. All analyses accounted for the complex design of the NIS-Teen
(32, 33) by applying appropriate sampling weights when determining proportions and effect
estimates. Frequencies are not weighted. Statistical tests were two-tailed with a critical alpha
of 0.05, with analyses conducted in SAS Version 9.2 (Cary, NC) using procedures for
complex survey data.
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The age distribution among daughters was fairly even, with each age having at least 17.0%
of the sample (Table 1). The race of most Hispanic daughters was white (86.1%), with fewer
black (5.6%) and other races (8.4%). About three-fourths of daughters had visited their
healthcare provider in the last year (77.6%) and lived in the state where they were born
(72.3%). Most mothers were at least 35 years old (85.3%), did not have any college
education (61.3%), and were married (65.5%). Just under half of parents completed the NIS-
Teen telephone survey in Spanish (44.6%). Most (81.2%) parents had heard of HPV, 83.3%
had heard of HPV vaccine, and 49.8% had received a recommendation from their healthcare
provider to get their daughters vaccinated.
Initiation
Overall, 60.9% of Hispanic adolescent females had received at least one dose of HPV
vaccine. Initiation increased from 56.2% in 2010 to 65.0% in 2011 (OR=1.47, 95% CI:
1.09-1.98), according to multivariate analyses (Table 2). HPV vaccine initiation was higher
among Hispanic daughters who were ages 16 (OR=1.89, 95% CI: 1.18-3.00) or 17
(OR=2.22, 95% CI: 1.41-3.51) compared to those who were age 13. Daughters were also
more likely to have initiated the HPV vaccine regimen if they had visited a healthcare
provider in the last year (OR=1.67, 95% CI: 1.09-2.56), had health insurance that was not
through their parent’s employer or union (OR=2.34, 95% CI: 1.37-3.98), had parents who
had received a provider recommendation to vaccinate (OR=1.63, 95% CI: 1.18-2.25), or
lived in households that contained multiple children. Compared to daughters from the West
region of the US, daughters living in the Midwest (OR=0.49, 95% CI: 0.31-0.77) or South
(OR=0.54, 95% CI: 0.37-0.77) regions were less likely to be initiators.
Completion
About 36.0% of Hispanic adolescent females had completed the three-dose HPV vaccine
regimen. Completion increased from 29.5% in 2010 to 41.6% in 2011 (OR=1.52, 95% CI:
1.11-2.08), according to multivariate analyses (Table 3). Completion was higher among
daughters who were ages 16 (OR=2.08, 95% CI: 1.32-3.29) or 17 (OR=1.85, 95% CI:
1.11-3.06), lived in the same state where they were born (OR=1.50, 95% CI: 1.05-2.17), had
health insurance through their parents’ employer or union (OR=1.84, 95% CI: 1.05-3.22), or
had some other type of health insurance (OR=3.00, 95% CI: 1.71-5.27). Daughters whose
mothers were ages 35-44 (OR=1.77, 95% CI: 1.09-2.89) or at least 45 years old (OR=1.68,
95% CI: 1.00-2.82) or whose parents had received a provider recommendation to vaccinate
(OR=1.60, 95% CI: 1.17-2.18) were also more likely to have completed the three-dose
regimen.
Follow-Through
Among initiators, 59.1% completed the HPV vaccine regimen (Table 4). In multivariate
analyses, daughters with health insurance that was not through their parents’ employer or
union (OR=2.40, 95% CI: 1.26-4.57) were more likely to follow-through the vaccine
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regimen after receiving the first dose compared to daughters without health insurance.
Follow-through was also higher among daughters whose mothers were 35-44 years old
(OR=2.29, 95% CI: 1.22-4.28) or at least 45 years old (OR=2.11, 95% CI: 1.08-4.14) or
whose mothers were college graduates (OR=2.39, 95% CI: 1.19-4.83). Follow-through was
lower among daughters from households containing at least four children (OR=0.42, 95%
CI: 0.22-0.81).
Intent to Vaccinate and Reasons for Not Intending to Vaccinate
Parents with unvaccinated daughters reported moderate intent to vaccinate in the next year
(mean=2.66, standard error [SE]=0.09). About 37.0% of these parents indicated their
daughters were “somewhat likely” or “very likely” to receive HPV vaccine in the next year.
Parents whose preferred language was Spanish reported higher intent to vaccinate
(mean=2.97, SE=0.15) compared to those whose preferred language was English
(mean=2.45, SE=0.11)(p<0.01; Figure 1).
The most common main reasons for parents not intending to vaccinate their daughters in the
next year were lack of knowledge (22.7%), concerns about vaccine safety and side effects
(21.1%), believing vaccination is not needed or not necessary (19.8%), daughter not being
sexually active (15.7%), and not having received a provider recommendation (10.2%)(Table
5). All other reasons were reported by less than 10.0% of parents. Compared to parents
whose preferred language was English, parents whose preferred language was Spanish were
more likely to indicate not having received a provider recommendation (20.2% vs. 5.3%)
and cost (10.9% vs. 1.8%) as a main reason for not intending to vaccinate (both p<0.05).
Spanish-speaking parents were less likely to report concerns about vaccine safety and side
effects as a main reason (5.9% vs. 28.5%; p<0.001).
Discussion
Hispanic women have higher cervical cancer incidence and mortality rates compared to non-
Hispanic white women (5). Despite these existing cervical cancer disparities, relatively little
research has examined HPV vaccination among this higher-risk population. Among a
national sample of Hispanic adolescent females, we found that just over 60% had initiated
the HPV vaccine regimen and only about one-third had received all three recommended
doses according to healthcare provider records. These estimates are noticeably higher than
those from the 2010 National Health Interview Survey (NHIS), which found only 31%
initiation and 12% completion among Hispanic adolescent females (37). However, the NHIS
vaccination data were not verified by medical records and relied solely on parent-reported
vaccination data. Furthermore, NHIS analyses included data on 11-12 year-olds, who often
have lower HPV vaccination coverage than older adolescents (38). Less than 60% of
Hispanic females in our study who received the first dose went on to complete the three-
dose regimen. This finding agrees with those from other US national studies (e.g., NHIS, the
National Health and Nutrition Examination Survey), where follow-through was typically
around 50% to 60% among adolescent females (11, 35, 37). Thus, many females who
receive the first dose fail to complete the vaccine regimen.
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Healthcare provider recommendation was one of the key determinants of HPV vaccination
among Hispanic adolescent females. Prior research similarly shows that provider
recommendation to be among the strongest correlates of HPV vaccination among adolescent
females (38-40). However, less than 50% of parents of Hispanic daughters in this study had
received a provider recommendation to vaccinate their daughters against HPV, despite over
75% of daughters having visited their providers in the last year. This finding suggests that
healthcare providers are missing many opportunities for recommending and administering
HPV vaccine to Hispanic adolescent females (41). Future efforts to increase provider
recommendation are likely key to increasing HPV vaccine coverage in this population.
HPV vaccination outcomes tended to be higher among older daughters and those with health
insurance. These findings support and extend those of past studies examining HPV
vaccination among adolescent females in the US (10, 38, 42, 43). Older adolescents likely
had more opportunities to initiate and complete the HPV vaccine regimen compared to
younger adolescents. However, targeting younger Hispanic adolescent females for HPV
vaccination is important since over 20% of Hispanic females self-report having sexual
intercourse by age 15 (44), putting them at risk of HPV infection. HPV vaccine is among the
most expensive vaccines available (45), and vaccine cost is a concern for some parents (40,
43), which may partially explain why vaccine coverage was lower among daughters without
health insurance. Lack of health insurance may be a particularly important barrier to HPV
vaccination among Hispanics, as they have the highest percentage of uninsured children of
any racial or ethnic group in the US (46). It is important that Hispanic parents are aware of
the Vaccines for Children (VFC) program, which can provide vaccines free of charge to
children meeting certain criteria (i.e., American Indian or Alaska native, Medicaid-eligible,
uninsured, or underinsured) (47). Although VFC eligibility was not associated with HPV
vaccination outcomes in our study, many of the daughters who had health insurance from
sources other than their parent’s employer or union likely received HPV vaccine through the
VFC program, as over half were covered by Medicaid.
Hispanic adolescent females who had moved from their birth state were less likely to have
completed the HPV vaccine regimen. It is possible that geographic mobility among these
adolescents disrupted their medical homes. Medical homes provide accessible and
continuous healthcare to adolescents (including vaccinations (48)), and adolescents without
a medical home may have more trouble obtaining the second and third doses of the HPV
vaccine regimen. Geographic mobility and its potential effect on HPV vaccination may be
important for the Hispanic population since about 80% of migrant and seasonal farm
workers are Hispanic (49). Research has shown that Hispanic farm workers lack awareness
and knowledge about HPV vaccine and access to care is a barrier to obtaining preventive
services for this population (50). Our results provide initial support that geographic mobility
may be associated with lower completion of the three-dose HPV vaccine regimen. However,
the NIS-Teen does not include information on when adolescents moved from their birth
state, leaving open the possibility that geographic mobility made it more difficult for the
NIS-Teen to obtain complete HPV vaccination histories from healthcare providers. Future
research is needed to clarify the relationship between geographic mobility and HPV
vaccination behaviors.
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Parents’ preferred language, our proxy measure of acculturation, was not associated with
past HPV vaccination. This finding is encouraging since a few studies have found lower
HPV vaccine coverage among Hispanics with less US acculturation (23, 24). However, we
did find that parents whose preferred language was Spanish reported higher intent to
vaccinate their daughters in the future, suggesting it will be important to monitor how
acculturation affects future trends in HPV vaccine coverage among Hispanic females.
Further, our results suggest that parents’ main reasons for not intending to vaccinate may
differ by preferred language. Spanish-speaking parents may be more concerned about cost of
HPV vaccine and be less likely to receive a healthcare provider recommendation to
vaccinate, while English-speaking parents with Hispanic daughters may be more concerned
about vaccine safety and potential side effects. In the current study, only 34.6% of Spanish-
speaking parents had received a healthcare provider recommendation to vaccinate compared
to 61.5% of English-speaking parents with Hispanic daughters. The lack of provider
recommendation among Spanish-speaking parents may be partly attributable to language
barriers and may also help explain why fewer of these parents reported concerns about
vaccine safety and potential side effects. It is possible that some of these parents do not
spend a great deal of time considering issues such as vaccine safety until after a healthcare
provider has discussed vaccination with them and provided a recommendation.
Regardless of preferred language, lack of knowledge among parents was a common reason
for not intending to vaccinate their daughters. Almost a quarter of parents in our analyses
indicated lack of knowledge as a main reason, which is noticeably higher than the 10.2% of
parents in the US (all races and ethnicities) who indicated this reason in 2010 (51). It is
important that future programs to increase HPV vaccination among Hispanics provide
information about HPV and HPV vaccine, while also considering how other potential
barriers to vaccination may differ by acculturation level.
Study strengths include using data from the NIS-Teen, which provided a large national
sample of Hispanic adolescent females and HPV vaccination data based on healthcare
provider records. We were also able to examine geographic mobility and parents’ preferred
language as potential correlates, variables which may be especially important to the
Hispanic population. Limitations include household response rates below 60% for the years
of NIS-Teen data analyzed. Although language preference correlates with acculturation
scales and is an important component of several of them, it is a proxy for acculturation (26).
The NIS-Teen public-use datasets did not contain information regarding country of origin
among Hispanics (e.g., Mexican, Cuban, etc.). Additional factors (e.g., parents’ health
beliefs (39, 52)) may be key determinants of HPV vaccination among Hispanics. Despite
these limitations, we believe our study represents an important early step in examining
correlates of HPV vaccination, parents’ intent to vaccinate, and reasons for not intending to
vaccinate among the Hispanic population.
HPV vaccination among Hispanic adolescent females in the US is suboptimal, with many
adolescents remaining unvaccinated. Similar to other racial and ethnic groups, efforts are
needed to increase healthcare provider recommendation for vaccination and to increase
vaccine coverage among younger adolescents and those without health insurance. Additional
factors, such as geographic mobility and preferred language, should also be considered when
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examining HPV vaccination among the Hispanic population and designing programs to
increase vaccination.
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Table 1




 2010 1199 (46.4)
 2011 1587 (53.6)
Daughter characteristics
Age
 13 yr 613 (20.3)
 14 yr 607 (19.2)
 15 yr 562 (24.1)
 16 yr 533 (19.4)
 17 yr 471 (17.0)
Race
 White 2389 (86.1)
 Black 160 (5.6)
 Other 237 (8.4)
Visited healthcare provider in last year
 No 525 (22.4)
 Yes 2233 (77.6)
Currently lives in state where born
 No 784 (27.7)
 Yes 2002 (72.3)
Healthcare coverage
 Through parent employer or union 1224 (37.1)
 Other insurance, including Medicaid 1184 (47.6)
 No insurance 357 (15.4)
Eligible for VFC program
 No 1320 (42.7)
 Yes 1458 (57.3)
Parent characteristics
Mother’s age
 <35 yr 346 (14.7)
 35-44 yr 1380 (51.2)
 45+ yr 1060 (34.1)
Mother’s education
 Less than high school 854 (39.4)
 High school 600 (21.9)
 Some college 691 (21.2)
 College graduate 641 (17.6)
Mother’s marital status
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n (weighted %)
 Not married 898 (34.5)
 Married 1888 (65.5)
Language of NIS-Teen interview
 English 1733 (55.4)
 Spanish 1048 (44.6)
Heard of HPV
 No 424 (18.8)
 Yes 2319 (81.2)
Heard of HPV vaccine
 No 309 (16.7)
 Yes 2446 (83.3)
Received provider recommendation to get daughter HPV vaccine
 No 1206 (50.2)
 Yes 1467 (49.8)
Household characteristics
Poverty status
 Below poverty 963 (43.3)
 Above poverty, ≤$75,000 1090 (40.0)
 Above poverty, >$75,000 612 (16.7)
Number of children in household
 1 873 (23.9)
 2-3 1490 (55.1)
 4+ 423 (21.0)
Region of residence
 Northeast 394 (12.5)
 Midwest 334 (9.9)
 South 1216 (32.1)
 West 842 (45.4)
Note. Totals may not sum to stated sample size due to missing data. Percents may not sum to 100% due to rounding. VFC = Vaccines for Children;
NIS-Teen = National Immunization Survey-Teen; HPV = human papillomavirus.
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Table 2
HPV vaccine initiation among Hispanic adolescent females (n=2,786)
No. Initiated / Total No. in
Category (weighted %) Bivariate OR (95% CI) Multivariate OR (95% CI)
Total 1639/2786 (60.9) -- --
Year
 2010 665/1199 (56.2) ref. ref.
 2011 974/1587 (65.0) 1.45 (1.09-1.93)* 1.47 (1.09-1.98)*
Daughter characteristics
Age
 13 yr 329/613 (52.0) ref. ref.
 14 yr 342/607 (58.7) 1.31 (0.86-1.99) 1.25 (0.79-1.96)
 15 yr 334/562 (58.0) 1.27 (0.81-2.00) 1.30 (0.81-2.09)
 16 yr 344/533 (66.2) 1.81 (1.17-2.79)* 1.89 (1.18-3.00)*
 17 yr 290/471 (72.2) 2.40 (1.56-3.70)** 2.22 (1.41-3.51)**
Race
 White 1389/2389 (60.7) ref. --
 Black 94/160 (63.8) 1.14 (0.67-1.96) --
 Other 156/237 (61.4) 1.03 (0.60-1.77) --
Visited healthcare provider in last year
 No 268/525 (47.9) ref. ref.
 Yes 1355/2233 (64.9) 2.01 (1.40-2.90)** 1.67 (1.09-2.56)*
Currently live in state where born
 No 449/784 (55.5) ref. --
 Yes 1190/2002 (63.0) 1.37 (1.00-1.86) --
Healthcare coverage
 Through parent employer or union 655/1224 (55.8) 1.53 (0.96-2.43) 1.19 (0.69-2.05)
 Other insurance, including Medicaid 788/1184 (69.5) 2.76 (1.73-4.41)** 2.34 (1.37-3.98)*
 No insurance 180/357 (45.2) ref. ref.
Eligible for VFC program
 No 711/1320 (58.5) ref. --
 Yes 926/1458 (62.8) 1.20 (0.90-1.60) --
Parent characteristics
Mother’s age
 <35 yr 219/346 (64.4) ref. --
 35-44 yr 841/1380 (60.9) 0.86 (0.55-1.36) --
 45+ yr 579/1060 (59.4) 0.81 (0.51-1.29) --
Mother’s education
 Less than high school 545/854 (64.3) ref. --
 High school 355/600 (63.0) 0.94 (0.64-1.38) --
 Some college 391/691 (55.7) 0.70 (0.47-1.02) --
 College graduate 348/641 (57.0) 0.73 (0.49-1.11) --
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No. Initiated / Total No. in
Category (weighted %) Bivariate OR (95% CI) Multivariate OR (95% CI)
Mother’s marital status
 Not married 565/898 (65.5) ref. --
 Married 1074/1888 (58.5) 0.74 (0.55-1.00) --
Language of NIS-Teen interview
 English 951/1733 (58.0) ref. --
 Spanish 685/1048 (64.5) 1.32 (0.98-1.77) --
Received provider recommendation to get daughter
HPV vaccine
 No 568/1206 (55.7) ref. ref.
 Yes 996/1467 (66.9) 1.61 (1.19-2.18)* 1.63 (1.18-2.25)*
Household characteristics
Poverty status
 Below poverty 626/963 (63.8) ref. --
 Above poverty, ≤$75,000 604/1090 (59.7) 0.84 (0.60-1.18) --
 Above poverty, >$75,000 330/612 (54.6) 0.68 (0.47-1.01) --
Number of children in household
 1 472/873 (54.6) ref. ref.
 2-3 910/1490 (61.6) 1.33 (0.98-1.81) 1.42 (1.02-1.98)*
 4+ 257/423 (66.4) 1.65 (1.06-2.55)* 1.78 (1.10-2.89)*
Region of residence
 Northeast 256/394 (64.2) 0.88 (0.60-1.28) 0.71 (0.47-1.07)
 Midwest 175/334 (53.6) 0.56 (0.37-0.86)* 0.49 (0.31-0.77)*
 South 685/1216 (53.0) 0.55 (0.39-0.78)** 0.54 (0.37-0.77)**
 West 523/842 (67.2) ref. ref.
Note. HPV = human papillomavirus; OR = odds ratio; CI = confidence interval; ref. = referent group; VFC = Vaccines for Children; NIS-Teen =
National Immunization Survey-Teen. Totals may not sum to stated sample size due to missing data. Multivariate model did not include variables
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Table 3
HPV vaccine completion among Hispanic adolescent females (n=2,786)
No. Completed / Total No.
in Category (weighted %) Bivariate OR (95% CI) Multivariate OR (95% CI)
Total 1025/2786 (36.0) -- --
Year
 2010 402/1199 (29.5) ref. ref.
 2011 623/1587 (41.6) 1.70 (1.27-2.28)** 1.52 (1.11-2.08)*
Daughter characteristics
Age
 13 yr 185/613 (27.5) ref. ref.
 14 yr 217/607 (34.7) 1.40 (0.91-2.17) 1.53 (0.94-2.47)
 15 yr 209/562 (34.3) 1.38 (0.87-2.19) 1.37 (0.85-2.21)
 16 yr 226/533 (43.6) 2.04 (1.31-3.16)* 2.08 (1.32-3.29)*
 17 yr 188/471 (41.2) 1.84 (1.16-2.92)* 1.85 (1.11-3.06)*
Race
 White 868/2389 (35.7) ref. --
 Black 64/160 (39.9) 1.20 (0.70-2.06) --
 Other 93/237 (36.8) 1.05 (0.62-1.79) --
Visited healthcare provider in last year
 No 156/525 (25.0) ref. ref.
 Yes 860/2233 (39.6) 1.97 (1.35-2.87)** 1.48 (0.98-2.23)
Currently live in state where born
 No 247/784 (27.4) ref. ref.
 Yes 778/2002 (39.3) 1.72 (1.22-2.42)* 1.50 (1.05-2.17)*
Healthcare coverage
 Through parent employer or union 440/1224 (35.7) 2.57 (1.56-4.24)** 1.84 (1.05-3.22)*
 Other insurance, including Medicaid 493/1184 (42.6) 3.44 (2.08-5.67)** 3.00 (1.71-5.27)**
 No insurance 84/357 (17.8) ref. ref.
Eligible for VFC program
 No 472/1320 (37.4) ref. --
 Yes 551/1458 (35.0) 0.90 (0.68-1.21) --
Parent characteristics
Mother’s age
 <35 yr 119/346 (26.9) ref. ref.
 35-44 yr 529/1380 (37.0) 1.60 (1.02-2.51)* 1.77 (1.09-2.89)*
 45+ yr 377/1060 (38.5) 1.70 (1.07-2.70)* 1.68 (1.00-2.82)*
Mother’s education
 Less than high school 307/854 (33.2) ref. --
 High school 222/600 (38.0) 1.23 (0.83-1.83) --
 Some college 263/691 (35.3) 1.10 (0.76-1.59) --
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No. Completed / Total No.
in Category (weighted %) Bivariate OR (95% CI) Multivariate OR (95% CI)
 College graduate 233/641 (40.5) 1.37 (0.90-2.07) --
Mother’s marital status
 Not married 346/898 (38.6) ref. --
 Married 679/1888 (34.7) 0.85 (0.63-1.14) --
Language of NIS-Teen interview
 English 600/1733 (35.3) ref. --
 Spanish 424/1048 (37.0) 1.08 (0.80-1.45) --
Received provider recommendation to get daughter
HPV vaccine
 No 327/1206 (29.8) ref. ref.
 Yes 645/1467 (41.9) 1.70 (1.25-2.31)** 1.60 (1.17-2.18)*
Household characteristics
Poverty status
 Below poverty 372/963 (36.3) ref. --
 Above poverty, ≤$75,000 387/1090 (35.8) 0.98 (0.70-1.37) --
 Above poverty, >$75,000 226/612 (38.4) 1.10 (0.75-1.60) --
Number of children in household
 1 313/873 (38.7) ref. ref.
 2-3 575/1490 (37.7) 0.96 (0.70-1.31) 1.11 (0.79-1.56)
 4+ 137/423 (28.5) 0.63 (0.40-0.99)* 0.86 (0.51-1.45)
Region of residence
 Northeast 175/394 (41.3) ref. ref.
 Midwest 104/334 (31.1) 0.64 (0.41-1.01) 0.72 (0.46-1.14)
 South 425/1216 (32.2) 0.67 (0.47-0.97)* 0.84 (0.57-1.25)
 West 321/842 (38.3) 0.88 (0.62-1.26) 1.19 (0.80-1.76)
Note. HPV = human papillomavirus; OR = odds ratio; CI = confidence interval; ref. = referent group; VFC = Vaccines for Children; NIS-Teen =
National Immunization Survey-Teen. Totals may not sum to stated sample size due to missing data. Multivariate model did not include variables
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Table 4
HPV vaccine follow-through among Hispanic adolescent females (n=1,639)a
No. Follow-Through /
Total No. in Category
(weighted %) Bivariate OR (95% CI) Multivariate OR (95% CI)
Total 1025/1639 (59.1) -- --
Year
 2010 402/665 (52.5) ref. ref.
 2011 623/974 (64.0) 1.61 (1.10-2.37)* 1.37 (0.92-2.05)
Daughter characteristics
Age
 13 yr 185/329 (52.9) ref. --
 14 yr 217/342 (59.2) 1.29 (0.71-2.34) --
 15 yr 209/334 (59.2) 1.29 (0.72-2.33) --
 16 yr 226/344 (65.9) 1.72 (0.95-3.12) --
 17 yr 188/290 (57.0) 1.18 (0.63-2.19) --
Race
 White 868/1389 (58.8) ref. --
 Black 64/94 (62.5) 1.17 (0.55-2.49) --
 Other 93/156 (60.0) 1.05 (0.54-2.06) --
Visited healthcare provider in last year
 No 156/268 (52.3) ref. --
 Yes 860/1355 (61.0) 1.43 (0.86-2.39) --
Currently live in state where born
 No 247/449 (49.3) ref. ref.
 Yes 778/1190 (62.4) 1.70 (1.12-2.60)* 1.53 (0.96-2.45)
Healthcare coverage
 Through parent employer or union 440/655 (64.0) 2.75 (1.45-5.21)* 1.98 (0.98-4.00)
 Other insurance, including Medicaid 493/788 (61.3) 2.45 (1.33-4.49)* 2.40 (1.26-4.57)*
 No insurance 84/180 (39.3) ref. ref.
Eligible for VFC program
 No 472/711 (63.9) ref. --
 Yes 551/926 (55.7) 0.71 (0.48-1.05) --
Parent characteristics
Mother’s age
 <35 yr 119/219 (41.7) ref. ref.
 35-44 yr 529/841 (60.7) 2.15 (1.24-3.75)* 2.29 (1.22-4.28)*
 45+ yr 377/579 (64.8) 2.57 (1.44-4.61)* 2.11 (1.08-4.14)*
Mother’s education
 Less than high school 307/545 (51.7) ref. ref.
 High school 222/355 (60.4) 1.43 (0.86-2.37) 1.49 (0.87-2.53)
 Some college 263/391 (63.5) 1.63 (0.98-2.71) 1.60 (0.91-2.81)
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No. Follow-Through /
Total No. in Category
(weighted %) Bivariate OR (95% CI) Multivariate OR (95% CI)
 College graduate 233/348 (71.0) 2.29 (1.35-3.88)* 2.39 (1.19-4.83)*
Mother’s marital status
 Not married 346/565 (58.9) ref. --
 Married 679/1074 (59.2) 1.01 (0.69-1.50) --
Language of NIS-Teen interview
 English 600/951 (60.8) ref. --
 Spanish 424/685 (57.3) 0.87 (0.59-1.27) --
Received provider recommendation to get daughter
HPV vaccine
 No 327/568 (53.5) ref. --
 Yes 645/996 (62.6) 1.46 (0.98-2.17) --
Household characteristics
Poverty status
 Below poverty 372/626 (57.0) ref. ref.
 Above poverty, ≤$75,000 387/604 (60.0) 1.13 (0.73-1.76) 0.71 (0.43-1.16)
 Above poverty, >$75,000 226/330 (70.4) 1.80 (1.08-2.99)* 0.78 (0.40-1.55)
Number of children in household
 1 313/472 (70.9) ref. ref.
 2-3 575/910 (61.2) 0.65 (0.42-0.99)* 0.67 (0.43-1.03)
 4+ 137/257 (42.9) 0.31 (0.17-0.55)** 0.42 (0.22-0.81)*
Region of residence
 Northeast 175/256 (64.4) 1.37 (0.86-2.17) --
 Midwest 104/175 (58.1) 1.05 (0.60-1.85) --
 South 425/685 (60.8) 1.17 (0.74-1.84) --
 West 321/523 (57.0) ref. --
Note. HPV = human papillomavirus; OR = odds ratio; CI = confidence interval; ref. = referent group; VFC = Vaccines for Children; NIS-Teen =
National Immunization Survey-Teen. Totals may not sum to stated sample size due to missing data. Multivariate model did not include variables
with dashes (--). Multivariate model included data on 1544 Hispanic adolescent females due to missing data for potential correlates.
a
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Table 5
Main reasons why parents did not intend to get their Hispanic adolescent daughters HPV vaccine in the next
year (n=560)
Total n (weighted %)
Parents’ Preferred Language
English n (weighted %) Spanish n (weighted %)
Lack of knowledge 89 (22.7) 56 (18.8) 32 (30.9)
Vaccine safety concern/side effects 156 (21.1) 132 (28.5) 24 (5.9)**
Vaccination not needed or not necessary 99 (19.8) 79 (16.8) 19 (26.1)
Daughter not sexually active 96 (15.7) 85 (18.7) 10 (9.4)
Did not receive provider recommendation 54 (10.2) 39 (5.3) 15 (20.2)*
Daughter not appropriate age 38 (5.1) 26 (5.5) 12 (4.2)
Costs 15 (4.7) 9 (1.8) 6 (10.9)*
Need more information/new vaccine 19 (3.6) 17 (4.6) 2 (1.6)
Daughter should make decision 11 (3.3) 8 (4.5) 3 (0.8)
Family/parent decision 20 (3.0) 20 (4.4) 0 (0.0)
Other reason 7 (0.9) 7 (1.4) 0 (0.0)
Handicapped/special needs/illness 5 (0.7) 3 (0.8) 2 (0.5)
Don’t believe in vaccinations 7 (0.6) 7 (0.9) 0 (0.0)
Not a school requirement 4 (0.4) 1 (0.1) 3 (1.1)
Daughter fearful 4 (0.3) 4 (0.4) 0 (0.0)
No doctor or doctor’s visit not scheduled 2 (0.3) 1 (0.3) 1 (0.2)
Religion/orthodox 2 (0.1) 2 (0.1) 0 (0.0)
Effectiveness concern 2 (0.1) 2 (0.2) 0 (0.0)
No obstetrician/gynocologist 1 (0.1) 1 (0.1) 0 (0.0)
Time 1 (<0.1) 0 (0.0) 1 (<0.1)
Note. Table includes parents of unvaccinated sons who indicated they were “not likely at all,” “not too likely,” or “not sure/don’t know” about
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